Sichuan Biokin Pharmaceutical (SHA:688506) said the first subject has been dosed in its global Phase III trial of BL-M14D1 combined with a PD-L1 inhibitor for first-line treatment in extensive-stage small cell lung cancer.
The study, comparing the ADC combo against chemotherapy plus PD-L1, is the world's first Phase III trial of ADC plus immunotherapy in this setting, according to a Friday filing with the Shanghai bourse.
Shares of the pharmaceutical company declined 2% in recent trade.
Xiamen Tungsten (SHA:600549) will avail of wealth management products for up to 2.1 billion yuan, according to a Thursday filing with the Shanghai bourse.The funds will be sourced from idle proceeds from its cash management program, the tungsten materials supplier said in its filing.Shares rose 6% during the midday break on Thursday.
Seiko Epson (TYO:6724) said its board agreed to launch an up to 30 billion yen buyback, repurchasing as many as 17 million common shares as part of its plan to drive growth investments and shareholder returns.The printer manufacturer said the share buyback will run from Aug. 7, 2026, through March 31, 2027, and all repurchased shares will be canceled, according to a Thursday filing on the Tokyo Stock Exchange.The buyback, to be conducted on the Tokyo Stock Exchange using the discretionary method, represents 5.31% of its outstanding shares excluding treasury stock.
CPE Technology's (KLSE:CPETECH) subsidiary, Champion Precision Technology, agreed to acquire a piece of freehold land with a factory in Johor, Malaysia, from Flomatic Industries, for 10 million ringgit, according to a Wednesday filing with Bursa Malaysia.The acquisition will be funded via proceeds from the company's initial public offering.The expansion is part of CPE's strategy to strengthen its manufacturing capabilities and expand production capacity.The transaction is expected to conclude by the second quarter of 2027, the filing said.